WO2020016432A1 - Poches contenant un principe actif reliées entre elles - Google Patents

Poches contenant un principe actif reliées entre elles Download PDF

Info

Publication number
WO2020016432A1
WO2020016432A1 PCT/EP2019/069559 EP2019069559W WO2020016432A1 WO 2020016432 A1 WO2020016432 A1 WO 2020016432A1 EP 2019069559 W EP2019069559 W EP 2019069559W WO 2020016432 A1 WO2020016432 A1 WO 2020016432A1
Authority
WO
WIPO (PCT)
Prior art keywords
active ingredient
pouch
product
composition
product according
Prior art date
Application number
PCT/EP2019/069559
Other languages
English (en)
Inventor
Nelly FRANSÉN
Lars WENSTER
Nils Siegbahn
Original Assignee
Niconovum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Niconovum Ab filed Critical Niconovum Ab
Priority to JP2021512494A priority Critical patent/JP7197071B2/ja
Priority to US17/250,423 priority patent/US20210235752A1/en
Priority to EP19742738.8A priority patent/EP3823473A1/fr
Priority to RU2021104128A priority patent/RU2769307C1/ru
Priority to MX2021000772A priority patent/MX2021000772A/es
Priority to CA3106859A priority patent/CA3106859C/fr
Publication of WO2020016432A1 publication Critical patent/WO2020016432A1/fr
Priority to JP2022190090A priority patent/JP2023022200A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F23/00—Cases for tobacco, snuff, or chewing tobacco
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B13/00—Tobacco for pipes, for cigars, e.g. cigar inserts, or for cigarettes; Chewing tobacco; Snuff
    • A24B13/02—Flakes or shreds of tobacco
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F23/00—Cases for tobacco, snuff, or chewing tobacco
    • A24F23/02—Tobacco pouches
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D33/00—Details of, or accessories for, sacks or bags
    • B65D33/008—Individual filled bags or pouches connected together

Definitions

  • the present invention relates to interconnected pouches comprising an active ingredient containing composition.
  • Buccal administration is a well-known technique for the administration of pharmacologically active ingredients, especially nicotine and nicotine-like stimulants.
  • Nicotine replacement therapy NRT is a medically-approved way to take nicotine as a method to quit smoking.
  • Known ways of administering NRT are for example by means of nicotine patches, nicotine lozenges, or nicotine pouches similar to snus pouches, adapted to be placed between the gum and the upper lip. Thereby, nicotine contained in said pouches may be absorbed by the user through the oral mucosa.
  • the amount of nicotine in each NRT pouch is often relatively low compared with the nicotine content of tobacco products such as snus.
  • a similar product is pouches/sachets containing snus, a way to consume tobacco without burning said tobacco.
  • Snus is a traditional Swedish product being a moist mixture of tobacco that is mostly placed between the gum and the upper lip. Thereby, nicotine contained in said snus may be absorbed by the user through the oral mucosa. Thus, snus is a way to absorb nicotine without the inhalation of smoke.
  • Another similar format is pouches/sachets containing nicotine without tobacco and without medical approval, sometimes named nicopods. The nicopods are mostly placed between the gum and the upper lip. Thereby, nicotine contained in said snus may be absorbed by the user through the oral mucosa.
  • the term nicotine-containing product is used herein to collectively describe all different formats.
  • the problem of having two or more pouches in the mouth at the same time is that they can be difficult to keep in place.
  • the consumer would be benefited by a stable placement of the pouches underneath the lip as this concentrates the composition to one place and prevents dilution and/or swallowing.
  • an active ingredient-containing product suitable for the release of an active ingredient comprising an outer water-permeable pouch chamber containing an active ingredient-containing composition
  • the product is characterised in that said pouch chamber is interconnected to another pouch chamber containing the same or another composition, thereby resulting in at least two interconnected pouch chambers each comprising a composition and wherein a separation section separates one pouch chamber from another.
  • the term "about” modifying the quantity of an ingredient in the active ingredient-containing product or composition or package of the invention or employed in the methods of the invention refers to variation in the numerical quantity that can occur, for example, through typical measuring and liquid handling procedures used for making concentrates or use solutions in the real world; through inadvertent error in these procedures; through differences in the manufacture, source, or purity of the ingredients employed to make the active ingredient-containing products or compositions, or to carry out the methods; and the like.
  • the term “about” also encompasses amounts that differ due to different equilibrium conditions for a composition resulting from a particular initial mixture. Whether or not modified by the term "about”, the claims include equivalents to the quantities.
  • an active ingredient-containing product suitable for the release of an active ingredient comprising an outer water-permeable pouch chamber containing an active ingredient-containing composition; wherein said pouch chamber is interconnected to another pouch chamber containing the same or another composition, thereby resulting in at least two interconnected pouch chambers each comprising a composition and wherein a separation section separates one pouch chamber from another, wherein each pouch chamber has a length of from about 1 mm to about 40 mm and a width of no greater than about 10 mm.
  • an active ingredient-containing product a product containing one or more active ingredients.
  • Active ingredients are characterised by having a pharmacological effect and may include nicotine, nicotine salts (e.g. nicotine ditartrate/nicotine bitartrate), nicotine-free tobacco substitutes, other alkaloids such as caffeine, medicinal products, or essential nutrients.
  • Medicinal products may include painkillers, allergy alleviating substances, or substances to treat motion sickness.
  • Essential nutrients may include vitamins and/or minerals.
  • Common for these types of active ingredients are their ability to be absorbed through the oral mucosa/gums or their ability to be dissolved in a liquid, e.g. water or have a local effect or sensation, such as nicotine-free tobacco substitutes.
  • the active ingredient is contained in an active ingredient-containing composition.
  • said active ingredient-containing composition is embodied in the active ingredient-containing product.
  • said nicotine may be contained as part of nicotine replacement therapy (NRT), tobacco snus, or tobacco free nicotine products without medical approval.
  • NRT nicotine replacement therapy
  • the product may be considered a nicotine-containing pharmaceutical product.
  • the active ingredient-containing product may be considered a nicotine-containing product when used with nicotine.
  • NRT is a medically-approved way to take nicotine by means other than tobacco. It is used to help with quitting smoking.
  • the active ingredient- containing product according to the invention may be used with a NRT composition, with tobacco, nicotine-free tobacco substitutes and with tobacco free nicotine.
  • the active ingredient-containing product may be used for medicinal purposes when used with medicinal substances, e.g. painkillers.
  • the active ingredient containing product comprises an active- ingredient containing composition that comprises nicotine or a nicotine-free tobacco substitute.
  • the nicotine may be contained as part of nicotine replacement therapy (NRT), tobacco snus, or tobacco free nicotine products without medical approval.
  • NRT nicotine replacement therapy
  • the product may be considered a nicotine- containing pharmaceutical product.
  • the active ingredient-containing product may be considered a nicotine-containing product when used with nicotine.
  • NRT is a medically-approved way to take nicotine by means other than tobacco. It is used to help with quitting smoking.
  • the active ingredient- containing product according to the invention may be used with a NRT composition, with tobacco, nicotine- free tobacco substitutes and with tobacco- free nicotine.
  • the active ingredient- containing product may thus be a nicotine-containing product or a nicotine-free tobacco substitute product.
  • each pouch chamber may have dimensions on the order of 1-4 cm.
  • each pouch chamber may have a length of more than 3 cm, e.g. 3.5 cm or 4 cm.
  • Each pouch chamber may have a length of from about 1 mm to about 40 mm and a width of no greater than about 10 mm.
  • each pouch chamber may have a width of less than about 10 mm. In some embodiments, each pouch chamber may have a width of from about 1 mm to about 10 mm, such as a width of from about 3 mm to about 10 mm, such as a width of from about 3 mm to about 9.5 mm, such as a width of from about 3 mm to about 9 mm, such as a width of from about 5 mm to about 9 mm, such as a width of from about 5 mm to about 7 mm. In some embodiments, each pouch chamber may have a width of from about 7 mm to about 9 mm.
  • each pouch chamber may have a length of from about 20 mm to about 40 mm and a width of no greater than about 10 mm. In some embodiments, each pouch chamber may have a length of from about 25 mm to about 40 mm and a width of no greater than about 10 mm.
  • the ratio of length to width of each pouch chamber is from about 3 to about 6, such as from about 3 to about 5, such as from about 3.5 to about 4.5.
  • the thickness of each pouch chamber may be from about 2 mm to about 8 mm, such as from about 3 mm to about 7 mm, such as from about 4 mm to about 6 mm. In some embodiments, the thickness of each pouch chamber may be from about 2 mm to about 3 mm.
  • the thickness of each pouch chamber may also be referred to as the “height” of the chamber, and is the dimension in a direction perpendicular to the width of the pouch chamber. The thickness may be measured as the height of the pouch chamber (in a non-compressed state) at the centre of the length of the pouch chamber, i.e. at half the maximum length of the pouch chamber.
  • the product may be suitable for immersion in liquid, whereby it is meant that the design and material choice of the product allow for such immersion, and where the active ingredient-containing composition is contained within the disclosed water- permeable pouch chamber.
  • the active ingredient may be allowed to dissolve in or to be released into said liquid.
  • the liquid may be water.
  • the product may resemble a tea bag.
  • the product allows for containing an active ingredient- containing composition, which may pass through the disclosed water-permeable pouch to be dissolved by liquid, e.g. saliva of the mouth in buccal administration or water in a glass during immersion.
  • the product is suitable for containing an at least partly dissolvable composition, where components of said composition may pass through the water-permeable pouch chamber.
  • a water-permeable pouch chamber is meant a pouch chamber comprising walls made of a water-permeable material, e.g. a textile or paper-like membrane.
  • a water-permeable material e.g. a textile or paper-like membrane.
  • saliva a fluid high in water
  • the pouch chamber is soaked over time, accelerating the release of components of the composition contained in said pouch chamber.
  • the release of components is likewise accelerated.
  • the active ingredient-containing composition is disposed within each pouch, whereupon said pouch is sealed, such that a chamber containing said active ingredient-containing composition is formed.
  • the pouch chamber being interconnected to another pouch chamber is meant that at least two pouch chambers are connected.
  • said pouch chambers are physically connected, but the content of the first pouch chamber is not in contact with the content of the second pouch chamber. Rather, the pouch chambers are connected by means of a section made of the water-permeable material, where said section may be made by means of welding said material together. In other words, the content of the first pouch chamber is not in communication with the content of the second pouch chamber.
  • the pouch chambers may be connected by means of a section made of the water-permeable material.
  • the separation section may be made by means of welding said material together.
  • more than two pouches chambers are interconnected.
  • 10, 15, or 20 pouch chambers may be interconnected by means of a separation section according to the invention.
  • the pouch chamber is referred to as a pouch for the remaining part of this document. Due to the separation section, the product may attain an uneven thickness (thickness variation), which, in combination with its flexibility, improves the ease of accommodation under the lip, as said lip adapts to the thickness variation, thereby holding the product in place better than what may be experienced in products not comprising such a separation section.
  • each of the pouches may contain an amount of active ingredient-containing composition not fulfilling the needs of most users, but due to said pouches being interconnected, the user may choose to tear off/detach two or more of said pouches, such that said user reaches his/her desired amount.
  • Such customisation is particularly relevant for use with nicotine-containing compositions, where the needs are highly individual for each user.
  • each of said pouches may be relatively small, which would be unpleasant to store in the mouth due to the risk of loss, but due to the provision of interconnected pouches, the product is more easily handled in the mouth.
  • most users may dispense two or three pouches at a time in order to fulfil his/her needs, whereby the pouches become easier to control in the mouth, due to their interconnected nature.
  • the user may easily adjust the amount by tearing off the desired number of pouches, which are thereby still interconnected, easing the handling.
  • the separation section is made of the water-permeable material and each pouch chamber may have a length of from about 1 mm to about 40 mm and a width of no greater than about 10 mm, such as a length of from about 1 mm to about 40 mm and a width of from about 3 mm to about 10 mm.
  • the storing of the product in a container is eased, which in turn provides an enhanced aesthetica l/visual impression, due to said pouches being interconnected.
  • the product according to the invention allows for the use of smaller storing containers, since the packaging procedure may be optimised and due to the pouches behaving in a predictable manner during packaging due to their interconnected nature.
  • the product may be less appealing to children, since the pouches are interconnected in a large row or array according to the invention, which does not readily express a product intended for oral use or individual use in general.
  • the product may comprise at least three pouch chambers and wherein opposing sides of one pouch chamber are connected to two other pouch chambers on opposing sides.
  • said pouches may be polygonally shaped, e.g. rectangular.
  • the product may resemble a row or chain of interconnected pouches.
  • Said row may comprise more than three pouches, e.g. 10, 15 or 20 pouches being interconnected.
  • using interconnected pouches allows for using length as a determining factor when determining the number of pouches to go into each package.
  • Using length as the determining factor e.g. instead of counting or mass, may be easier in certain configurations of the packaging machinery. For example, using length is easier than to integrate a scale for measuring the mass of the pouches in each package.
  • the product may comprise at least three pouch chambers and wherein neighbouring sides of one pouch chamber are connected to two other pouch chambers on neighbouring sides.
  • the product comprises at least three pouch chambers, wherein two neighbouring sides of one pouch chamber are each connected to distinct pouch chambers. In some embodiments, the product comprises at least four pouch chambers, wherein three neighbouring sides of on pouch chamber are connected to three other pouch chambers.
  • the product may form an array of interconnected pouch chambers.
  • array of pouch chambers may allow for certain advantages in the packaging procedure, including space optimisation and aesthetical features.
  • the area or dimensions of the array may be used to determine the number of pouches, such that the packaging procedure may be optimised.
  • the array may be considered a two-dimensional sheet of pouches being interconnected.
  • the separation section may comprise a separation line.
  • a separation line is meant a line easing the detachment of one pouch chamber from another.
  • the separation line is of a strength such that one pouch chamber is not detached from another during use.
  • the strength may decrease once the water-permeable material used to form the pouch, and thereby the separation section, is soaked with liquid/saliva.
  • the separation line may comprise a row of perforations or holes enabling detachment of the one pouch chamber form the other pouch chamber by ripping.
  • the separation line may comprise a row of perforations or holes enabling detachment of the one pouch chamber form the other pouch chamber by ripping, tearing or cutting.
  • a convenient and easy-to-use separation line may be employed.
  • the separation section may be made by welding opposite pouch surfaces together, whereby the separation section is a welding section between neighbouring pouch chambers.
  • the pouches may be made from a long tube of the desired water-permeable material, where sidewalls of said tube are welded together, in a way such that no active ingredient- containing composition is arranged within the formed welding section.
  • the welding section ensures that said active ingredient-containing composition is contained within the individual pouch chambers defined by said welding section and the sidewalls.
  • the welding section may be shaped ensuring an efficient separation and minimizing the area of the separation section.
  • the welding section may be curved, which may ease the process of detaching the interconnected pouches from each other.
  • the welding section may have a width being smaller than a width of each pouch, such that the user does not need to tear a great distance. Such shape reduces the amount of material used.
  • the at least two interconnected pouch chambers may comprise a first and a second composition, respectively, wherein said first composition is different from said second composition.
  • at least one of the first and second compositions comprises nicotine or a nicotine-free tobacco substitute.
  • the first pouch may comprise a first composition
  • the second pouch may comprise a second composition being different from the first composition.
  • the user is capable of mixing the pouches he/she inserts into the
  • a division of the content within each of said the pouches may be beneficial in case said content is not suitable for mixing prior to use, or if the user wants to control what combinations he/she wants.
  • At least one of the active ingredient-containing compositions comprises a flavouring agent.
  • the flavouring agent may be included in the same active ingredient-containing composition as the nicotine and/or tobacco substitute.
  • the first active ingredient-containing composition may comprise nicotine and/or tobacco substitute, and the second active ingredient-containing composition may comprise the flavouring agent.
  • the first composition may be a flavour composition.
  • flavour and “flavourant” refer to materials which, where local regulations permit, may be used to create a desired taste or aroma in a product for adult consumers. They may include extracts (e.g., licorice, hydrangea, Japanese white bark magnolia leaf, chamomile, fenugreek, clove, menthol, Japanese mint, aniseed, cinnamon, herb, wintergreen, cherry, berry, peach, apple, Drambuie, bourbon, scotch, whiskey, spearmint, peppermint, lavender, cardamom, celery, cascarilla, nutmeg, sandalwood, bergamot, geranium, honey essence, rose oil, vanilla, lemon oil, orange oil, cassia, caraway, cognac, jasmine, ylang-ylang, sage, fennel, piment, ginger, anise, coriander, coffee, or
  • the first composition may be a mixture of a flavour composition and an active ingredient-containing composition, such that said first composition provides a flavour, on the cost of a reduced amount of the active ingredient-containing composition. Said reduced amount may be compensated by a non-flavoured second composition comprising the pure active ingredient-containing composition. Since the user is capable of dispensing/inserting two interconnected pouches at a time, the ease of use is enhanced.
  • the first composition may be suitable for adding a flavour to the experience of the product.
  • the product may comprise at least 10 interconnected pouch chambers comprising said first and second interconnected pouches.
  • the product comprises multiple interconnected pouches, e.g. arranged in a row or in an array.
  • Such multiple interconnected pouches may more easily be arranged in a package/container, such that the size of said package/container may be reduced.
  • the packaging procedure may be sped up due to the pouches being interconnected and as such behave predictably.
  • length or area may be used instead of mass or counting when determining the number of pouches during the packaging process.
  • the active ingredient-containing composition may comprise nicotine.
  • At least one of the first and second compositions may comprise nicotine.
  • the nicotine may be embodied as NRT, snus, various form of tobacco, tobacco-free nicotine products or nicotine salts.
  • the active ingredient-containing composition may be considered a nicotine-containing composition.
  • the at least one of the first and second compositions may be considered to be a nicotine- containing composition.
  • a product comprising such a nicotine-containing composition may be beneficial within the field of nicotine consumption, e.g. by providing additional consumption options to the users.
  • the active ingredient-containing composition comprises tobacco.
  • at least one of the first and second compositions may comprise tobacco.
  • the active ingredient-containing composition is a“smokeless oral tobacco product”.
  • tobacco as used herein includes any part, such as the leaves, flowers, or stems, of any member of the genus Nicotiana and reconstituted materials thereof. In some embodiments, it includes treated tobacco. In some embodiments, it includes derivatives such as specific compounds found in natural tobacco, such as nicotine, whether extract or synthesized, as well as structural derivatives such as the fibrous portion of a tobacco leaf.
  • tobacco extract includes tobacco extract.
  • the amount of stem in the tobacco blend may be up to 50%, up to 60%, or up to 70% by weight of the tobacco.
  • the amount of stem in the tobacco is from 5% to 70% by weight of the tobacco, such as from 10% to 65% by weight of the tobacco, such as from 15% to 65% by weight of the tobacco, such as from 20% to 60% by weight of the tobacco, such as from 25% to 55% by weight of the tobacco, such as from 30% to 50% by weight of the tobacco.
  • Tobaccos used in the present invention may include types of tobaccos such as dark air-cured tobacco, flue-cured tobacco, Burley tobacco, Oriental tobacco, Maryland tobacco, dark tobacco, dark-fired tobacco and Rustica tobaccos, as well as other rare or specialty tobaccos.
  • types of tobaccos such as dark air- cured tobacco, flue-cured tobacco, Burley tobacco, Oriental tobacco, Maryland tobacco, dark tobacco, dark-fired tobacco and Rustica tobaccos, as well as other rare or specialty tobaccos.
  • the tobacco may be whole, shredded, threshed, cut, ground, cured, aged, fermented, or otherwise treated (e.g. granulated or encapsulated).
  • the tobacco is ground tobacco and/or is in particulate form.
  • the tobacco is in the form of strands or cut lamina.
  • the tobacco may be snuff in dry or moist form.
  • “Snuff is used herein to generally describe a class of smokeless tobacco product which typically comprises cured tobacco which has been dried and ground to have mass median particle size measured by sieve analysis of between 0.01 and 5mm, such as between 0.01 and 3mm, such as between 0.01 and 1.0 mm.
  • the tobacco may be dry snuff.
  • the moisture content of the tobacco is less than 16% by weight of the total smokeless oral tobacco product, such as less than 12% by weight of the total active ingredient-containing product, such as less than 10% by weight of the total active ingredient-containing product, such as less than 5% by weight of the total active ingredient-containing product, such as less than 3% by weight of the total active ingredient-containing product, such as less than 2% by weight of the active ingredient-containing product, such as less than 1% by weight of the total active ingredient-containing product.
  • the tobacco is in moist form.
  • the moist tobacco may be in any form that is suitable for incorporation into a smokeless oral tobacco product.
  • the moist tobacco comprises moist snuff.
  • the moist snuff comprises Swedish-style snuff, which may also be referred to as snus-style tobacco or snus.
  • the moist snuff is Swedish-style snuff (snus).
  • Snus is a moist powder tobacco product originating from a variant of dry snuff.
  • snus is an oral tobacco product which is not fermented, but is rather heat-treated, such as by pasteurisation. Snus is typically used by placing it under the upper lip for extended periods of time.
  • the moisture content of the tobacco is at least 20% by weight of the total active ingredient-containing composition, such as at least 25% by weight of the active ingredient-containing composition, such as at least 30% by weight of the active ingredient-containing composition, such as at least 35% by weight of the active ingredient-containing composition, such as at least 40% by weight of the active ingredient-containing composition, such as at least 45% by weight of the active ingredient-containing composition, such as at least 50% by weight of the active ingredient-containing composition, such as at least 60% by weight of the active ingredient-containing composition.
  • the moisture content of the tobacco is from about 20% to about 60% by weight of the active-ingredient containing composition.
  • the term“moisture content” refers to the total amount of oven volatiles ingredients, such as water and other oven volatiles (e.g. propylene glycol) in the composition or product referred to.
  • the snus may comprise salt and/or other flavourants.
  • the snus may be pasteurised or may undergo a process similar to pasteurisation and may optionally be matured, to reach the desired pH and/or moisture content of the snus. Methods and apparatus suitable for pasteurisation and maturation are known to the person skilled in the art.
  • the active ingredient-containing composition comprises a tobacco composition comprising tobacco (e.g. ground or cut tobacco), water, salt (e.g. sodium chloride, potassium chloride, magnesium chloride, calcium chloride, or mixtures thereof), pH adjuster, and optionally one or more flavouring agents, cooling agents, heating agents, sweetening agents, colouring agents, humectants, preservatives, binders, fillers, or mixtures thereof.
  • tobacco e.g. ground or cut tobacco
  • salt e.g. sodium chloride, potassium chloride, magnesium chloride, calcium chloride, or mixtures thereof
  • pH adjuster e.g. sodium chloride, potassium chloride, magnesium chloride, calcium chloride, or mixtures thereof
  • flavouring agents e.g. sodium chloride, potassium chloride, magnesium chloride, calcium chloride, or mixtures thereof
  • cooling agents e.g. sodium chloride, potassium chloride, magnesium chloride, calcium chloride, or mixtures thereof
  • sweetening agents e.g. sodium chloride, potassium chloride,
  • the moist snuff may be in the form of dipping tobacco.
  • the dipping tobacco may be treated by fermentation or may undergo a process similar to fermentation and may optionally undergo one or more further processes such as aging. Methods and apparatus suitable for the treatment of dipping tobacco are known to the person skilled in the art.
  • the tobacco may be in the form of US moist snuff and/or chewing tobacco.
  • the amount of tobacco within the active-ingredient containing product may vary.
  • the amount of tobacco within the active ingredient-containing product is at least about 5% by weight of the active ingredient-containing product, such as at least about 10% by weight of the active ingredient-containing product, such as at least about 15% by weight of the active ingredient-containing product, such as at least about 20% by weight of the active ingredient-containing product, such as at least about 25% by weight of the active ingredient-containing product , such as at least about 30% by weight of the active ingredient-containing product, such as at least about 40% by weight of the active ingredient-containing product, such as at least about 50% by weight of the active ingredient-containing product, such as at least about 55% by weight of the active ingredient-containing product, such as at least about 60% by weight of the active ingredient-containing product.
  • the amount of tobacco within the active ingredient-containing product is no greater than about 90% by weight of the active ingredient-containing product, such as no greater than about 85% by weight of the active ingredient-containing product, such as no greater than about 80% by weight of the active ingredient-containing product, such as no greater than about 75% by weight of the active ingredient-containing product, such as no greater than about 70% by weight of the active ingredient-containing product.
  • the amount of tobacco within the active ingredient-containing product is between about 20% and 90% by weight of the active ingredient-containing product, such as between 20% and 85% by weight of the active ingredient-containing product, such as between about 20% and 80% by weight of the active ingredient- containing product, such as between about 20% and 75% by weight of the active ingredient-containing product, such as between about 20% and 70% by weight of the active ingredient-containing product, such as between about 20% and 65% by weight of the active ingredient-containing product, such as between about 20% and 60% by weight of the active ingredient-containing product, such as between about 25% and 60% by weight of the active ingredient-containing product, such as between about 30% and 60% by weight of the active ingredient-containing product, such as between about 35% and 60% by weight of the active ingredient-containing product.
  • the active ingredient-containing composition may comprise a nicotine- free tobacco substitute.
  • At least one of the first and second compositions may comprise a nicotine-free tobacco substitute.
  • tobacco substitute includes tobacco substitutes which comprise individual chemicals and/or complex chemical entities which, when appropriately prepared, physically resemble natural tobacco.
  • tobacco substitute as used herein includes materials which provide a similar mouthfeel to tobacco and deliver local and/or pharmacological sensations provided by tobacco.
  • a nicotine-free tobacco substitute is meant a composition being nicotine-free, yet providing certain active ingredients that result in the local and/or pharmacological sensations provided by tobacco.
  • the tobacco substitute may comprise a blend of select natural products, e.g. nicotine-free plant material.
  • the active ingredient-containing composition comprises a nicotine- free tobacco substitute
  • the nicotine-free tobacco substitute comprises nontobacco plant material, salt (e.g. sodium chloride, potassium chloride, magnesium chloride, calcium chloride, or mixtures thereof), pH adjuster, and optionally one or more flavouring agents, cooling agents, heating agents, sweetening agents, colouring agents, humectants, preservatives, binders, fillers, or mixtures thereof.
  • the tobacco substitute comprises non-tobacco plant material.
  • non-tobacco plant material used in the tobacco substitute are dietary plant fibres such as maize fibres, oat fibres, tomato fibres, barley fibres, rye fibres, sugar beet fibres, buck wheat fibres, potato fibres, apple fibres, cocoa fibres, bamboo fibres, citrus fibres, and combinations thereof.
  • the user may choose to consume a tobacco-like composition without the consumption of nicotine.
  • the active ingredient-containing composition may comprise a medicament.
  • the medicament may be included in the same active ingredient- containing composition as nicotine and/or tobacco substitute.
  • a first active ingredient-containing composition in one pouch chamber may comprise nicotine and/or tobacco substitute
  • a second active ingredient-containing composition in a second pouch chamber may comprise the medicament.
  • a medicament is meant a substance providing an alleviation or prevention of symptoms or providing a treatment of a disease.
  • the medicament may be intended for absorption through the mucosa/gum, i.e. suitable for buccal administration through a product according to the invention, or the medicament may be intended for dissolving in a liquid, i.e. suitable for immersion through a product according to the invention.
  • An effervescent effect may be added to the composition.
  • the user may easily be treated for a relevant disease or alleviated from a relevant symptom by use of a product according to the invention comprising such relevant medicament.
  • the medicament may be paracetamol.
  • the active ingredient-containing composition may comprise an essential nutrient.
  • the essential nutrient may be included in the same active ingredient-containing composition as nicotine and/or tobacco substitute.
  • a first active ingredient-containing composition in one pouch chamber may comprise nicotine and/or tobacco substitute
  • a second active ingredient-containing composition in a second pouch chamber may comprise the essential nutrient.
  • an essential nutrient is meant vitamins or minerals.
  • the user may easily consume such essential nutrient, either by immersion the product according to the invention in a liquid, whereby said nutrient is released into said liquid, or through buccal administration.
  • a disintegrating pouch may be used.
  • An effervescent effect may be added to the composition.
  • the active ingredient-containing composition may comprise an alkaloid.
  • the alkaloid may be included in the same active ingredient-containing composition as nicotine and/or tobacco substitute.
  • a first active ingredient-containing composition in one pouch chamber may comprise nicotine and/or tobacco substitute
  • a second active ingredient-containing composition in a second pouch chamber may comprise the alkaloid.
  • alkaloids plant derived components with pharmacological effects - for example caffeine.
  • the user may easily consume such alkaloid, either by immersion the product according to the invention in a liquid, whereby said nutrient is released into said liquid, or through buccal administration.
  • a disintegrating pouch may be used.
  • An effervescent effect may be added to the composition.
  • the active ingredient may be selected from the group consisting of active pharmaceutical substances, food additives, natural medicaments, or naturally occurring substances that can have an effect on humans.
  • the active ingredient may be selected from the group consisting of caffeine, nicotine, vitamin B12, vitamin C, vitamin E, bioperin, Q10, selenium, glutathione, liponic acid, folic acid, ginseng, pollen extract, antioxidants, minerals, paracetamol, acetylsalicylic acid, Russian root and rose root.
  • the active ingredient may be selected from the group consisting of nicotine, cannabis, a cannabinoid or mixtures thereof.
  • Cannabinoids are a class of natural or synthetic chemical compounds which act on cannabinoid receptors (i.e., CB1 and CB2) in cells that repress neurotransmitter re-lease in the brain. Two of the most important cannabinoids are tetrahydrocannabinol (THC) and cannabidiol (CBD).
  • Cannabinoids may be naturally occurring (Phytocannabinoids) from plants such as cannabis, (endocannabinoids) from animals, and artificially manufactured (Synthetic cannabinoids).
  • Cannabinoids are cyclic molecules exhibiting particular properties such as the ability to easily cross the blood-brain barrier, weak toxicity, and few side effects. Cannabis species express at least 85 different phytocannabinoids, and are divided into subclasses, including cannabigerols, cannabichromenes, cannabidiols, tetrahydrocannabinols, cannabinols and cannabinodiols, and other cannabinoids.
  • Cannabinoids found in cannabis include, without limitation: cannabigerol (CBG), cannabichromene (CBC), cannabidiol (CBD), tetrahydrocannabinol (THC), cannabinol (CBN) and cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid (CBDA), Cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabmolic acid (THCA), and tetrahydrocannabivarinic acid (THCV A).
  • CBD cannabigerol
  • the active ingredient-containing composition comprises a flavouring agent.
  • flavouring agent refers to materials which, where local regulations permit, may be used to create a desired taste or aroma in a product for adult consumers. They may include extracts (e.g., licorice, hydrangea, Japanese white bark magnolia leaf, chamomile, fenugreek, clove, menthol, Japanese mint, aniseed, cinnamon, herb, wintergreen, cherry, berry, peach, apple, Drambuie, bourbon, scotch, whiskey, spearmint, peppermint, lavender, cardamom, celery, cascarilla, nutmeg, sandalwood, bergamot, geranium, honey essence, rose oil, vanilla, lemon oil, orange oil, cassia, caraway, cognac, jasmine, ylang-ylang, sage, fennel, piment, ginger, anise, coriander, coffee, or
  • the invention relates to a package comprising a product according to the previous disclosures.
  • a package By a package is meant a container capable of storing the at least two interconnected pouches according to the previous disclosures.
  • the container is capable of storing a plurality of interconnected pouches, e.g. 10, 15 or 20 interconnected pouches, such that said pouches are disposed as an interconnected row/chain or array within said package/container.
  • FIG. 1 illustrates a perspective view of an active ingredient-containing product according to the invention
  • Fig. 2 illustrates a side view of an active ingredient-containing product according to the invention
  • Fig. 3 illustrates a side view of a plurality of active ingredient-containing products according to the invention
  • Fig. 4 illustrates an array of an active ingredient-containing product according to the invention.
  • Fig. 5 illustrates a package comprising a product according to previous disclosures.
  • Fig. 1 illustrates a perspective view of an active ingredient-containing product 100 according to the invention.
  • the product 100 comprises at least two pouches 101 , also referred to as pouch chambers, interconnected by means of a separation section 102.
  • Each of said pouches 101 encloses a composition, e.g. an active ingredient-containing composition (not shown).
  • Each of said pouches 101 has dimensions making it suitable for insertion into the mouth of the user (buccal administration), e.g. a length or width in the order of 1-4 cm.
  • two or more interconnected pouches 101 have combined dimensions likewise making them suitable for insertion into the mouth (buccal administration), such that the user may accommodate multiple interconnected pouches 101 in his/her mouth.
  • a single pouch 101 may contain an amount of an active ingredient-containing composition less than what would be commonly used, e.g. less than what causes an effect/medical response in most individuals.
  • the user may choose to dispense more than one pouch, e.g. two or three pouches, depending on his/her tolerance for the enclosed nicotine-containing composition. Due to the interconnected nature, the pouches 101 may more easily be stored/accommodated in the mouth, e.g. without risk of losing/swallowing. In fact, a single pouch 101 may be too small to most individuals, whereas two or more interconnected pouches would constitute a preferred size.
  • the pouches 101 are made of a water-permeable material 103 allowing liquid/water, or saliva of the mouth, to soak the composition enclosed by said pouches 101 , thereby accelerating the release of components of said composition, e.g. its active ingredients.
  • the water-permeable material 103 allows water and components dissolved therein to pass through, such that said components may be dissolved in the liquid or absorbed by the user, e.g. into the blood vessels through the mucosa/gums.
  • the water-permeable material 103 has a wet strength selected such that said material does not disintegrate once soaked with water/saliva, since such disintegration would cause the enclosed composition to enter the digestive system of the user, which may be harmful or not provide any effect at all.
  • the water-permeable material 103 is made of a textile or paper-like membrane.
  • a first cross-section A and a second cross-section B of the pouches 101 are highlighted by dashed lines, illustrating the inner volume/chamber 104 intended for accommodating the active ingredient-containing composition.
  • Each of said pouches 101 are divided by a separation section 102, e.g. formed by welding opposing sidewalls of the water-permeable material 103 together, whereby said separation section 103 may be considered a welding section.
  • Dashed lines C indicate a possible continuation of the product 100, whereby said product 100 may comprise more than two interconnected pouches 101 , and such that each of said pouches 101 are mutually interconnected to its neighbouring pouches by means of a separation section 102, and such that said pouches 101 extend in a row.
  • Fig. 2 illustrates a side view of three embodiments of the product 100, where like elements according to Fig. 1 are provided with like reference numbers. All embodiments illustrate a separation line 1 12 arranged within the separation section 102. Preferably, said separation line 1 12 comprises a row of perforations or holes made in the material used to form the separation section 102, said separation line 1 12 enabling detachment of one pouch 101 from another by means of ripping.
  • the dotted inner volume 104 illustrates the active ingredient-containing composition 105.
  • the separation section 102 and separation line 1 12 are straight, whereas Fig. 2b illustrates the case where said separation section 102 and separation line 1 12 are curved.
  • Fig. 2c illustrates two interconnected pouches 101 separated by a separation section 102 being substantially shorter than a maximum width W of each pouch 101 . Thereby, the amount of material used to separate each pouch 101 may be reduced. Further, the separation may more easily be performed by the user.
  • Fig. 3 illustrates a row/chain of a plurality of interconnected pouches 101 forming a product 100 according to the invention.
  • opposing sides 101a, 101 b of one pouch 101 are connected to two other pouches 101 on likewise opposing sides 101 a’, 101 b’.
  • a row of a plurality of interconnected pouches 101 may for example be stored in a spiral fashion in a circular package/container (not shown, see Fig. 5a).
  • Fig. 4 illustrates an array of interconnected pouches 101 forming a product 100 according to the invention.
  • neighbouring sides 101 a, 101 c of one pouch 101 are connected to two other pouch chambers on likewise opposing sides 101 a’, 101 c’, thereby forming an array.
  • An array may easily be stored in a package/container (not shown, see Fig. 5b).
  • Fig. 5 illustrates two embodiments of a package/container 200 comprising a product 100 according to previous disclosures.
  • Fig. 5a illustrates a circular package 200a having sidewalls 201 , a bottom 202, and an open end 203 adapted to receive interconnected pouches 101 according to the invention. The open end 203 is closable using a lid 204.
  • the interconnected pouches 101 may be stored in a spiral-like fashion, as indicated by the spiral in the figure.
  • Fig. 5b illustrates a quadrangular package 200b having the same features as the circular package of Fig. 5a (like features being equipped with like reference numbers), said quadrangular package 200b being capable of storing an array of interconnected pouches 101 as illustrated in Fig. 4.
  • these and further aspects of the present invention have been discussed under appropriate section headings. However, the teachings under each section are not necessarily limited to each particular section.
  • an active ingredient-containing product suitable for the release of an active ingredient comprising an outer water-permeable pouch chamber containing an active ingredient-containing composition; wherein said pouch chamber is interconnected to another pouch chamber containing the same or another composition, thereby resulting in at least two interconnected pouch chambers each comprising a composition, wherein a separation section separates one pouch chamber from another, and wherein each pouch chamber has a length of from about 1 mm to about 40 mm and a width of from about 3 mm to about 25 mm.
  • each pouch chamber may have a width of from about 3 mm to about 25 mm. In some embodiments, each pouch chamber may have a width of from about 5 mm to about 20 mm, such as from about 10 mm to about 20 mm, such as from about 10 mm to about 15 mm. In some embodiments, each pouch chamber may have a width of from about 5 mm to about 15 mm.
  • each pouch chamber may have a length of from about 1 mm to about 40 mm and a width of from about 5 mm to about 20 mm. In some embodiments, each pouch chamber may have a length of from about 1 mm to about 40 mm and a width of from about 10 mm to about 20 mm. In some embodiments, each pouch chamber may have a length of from about 1 mm to about 40 mm and a width of from about 10 mm to about 15 mm. In some embodiments, each pouch chamber may have a length of from about 1 mm to about 40 mm and a width of from about 5 mm to about 15 mm.
  • each pouch chamber may have a length of from about 20 mm to about 40 mm and a width of from about 5 mm to about 20 mm. In some embodiments, each pouch chamber may have a length of from about 25 mm to about 40 mm and a width of from about 5 mm to about 20 mm. In some embodiments, the thickness of each pouch chamber may be from about 2 mm to about 8 mm, such as from about 3 mm to about 7 mm, such as from about 4 mm to about 6 mm. In some embodiments, the thickness of each pouch chamber may be from about 2 mm to about 3 mm. In some embodiments, the active ingredient-containing product may be a nicotine-containing product or a nicotine-free tobacco substitute product. In some embodiments, the active ingredient-containing composition may comprise nicotine. For example, the active ingredient-containing composition may comprise tobacco. In some embodiments, the active ingredient-containing composition may comprise a nicotine-free tobacco substitute.
  • the active ingredient-containing product according to this aspect includes any of the features as described hereinabove, with reference to the general description and detailed description.
  • an active ingredient-containing product suitable for the release of an active ingredient, said active ingredient-containing product comprising an outer water- permeable pouch chamber containing an active ingredient-containing composition; wherein said pouch chamber is interconnected to another pouch chamber containing the same or another composition, thereby resulting in at least two interconnected pouch chambers each comprising a composition, wherein a separation section separates one pouch chamber from another, wherein said at least two interconnected pouch chambers comprise a first and a second composition, respectively, wherein said first composition is different from said second composition, and wherein at least one of the first and second compositions comprises nicotine or a nicotine-free tobacco substitute.
  • the active ingredient-containing product includes any of the features as described hereinabove, with reference to the general description and detailed description.
  • the invention will now be described in further detail in the following numbered
  • An active ingredient-containing product suitable for the release of an active ingredient comprising an outer water- permeable pouch chamber containing an active ingredient-containing composition; characterised in that said pouch chamber is interconnected to another pouch chamber containing the same or another composition, thereby resulting in at least two interconnected pouch chambers each comprising a composition and wherein a separation section separates one pouch chamber from another.
  • a product according to paragraph 1 wherein said product comprises at least three pouch chambers and wherein opposing sides of one pouch chamber are connected to two other pouch chambers on opposing sides.
  • a product according to paragraph 1 wherein said product comprises at least three pouch chambers and wherein neighbouring sides of one pouch chamber are connected to two other pouch chambers on neighbouring sides.
  • said separation line comprises a row of perforations or holes enabling detachment of the one pouch chamber from the other pouch chamber by ripping.
  • the separation section is a welding section between neighbouring pouch chambers.
  • said at least two interconnected pouch chambers comprise a first and a second composition, respectively, wherein said first composition is different from said second composition.
  • a package comprising a product according to paragraphs 1-15.

Landscapes

  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Packages (AREA)

Abstract

L'invention concerne un produit contenant un principe actif convenant pour la libération d'un principe actif, comprenant une chambre de poche externe perméable à l'eau contenant une composition contenant un principe actif. Dans le produit, ladite chambre de poche est reliée à une autre chambre de poche contenant la même composition ou une autre composition, ce qui permet d'obtenir au moins deux chambres de poche reliées entre elles, chacune comprenant une composition, une section de séparation séparant une chambre de poche d'une autre. Chaque chambre de poche a une longueur d'environ 1 mm à environ 40 mm et une largeur ne dépassant pas environ 10 mm
PCT/EP2019/069559 2018-07-19 2019-07-19 Poches contenant un principe actif reliées entre elles WO2020016432A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2021512494A JP7197071B2 (ja) 2018-07-19 2019-07-19 相互接続された活性成分含有パウチ
US17/250,423 US20210235752A1 (en) 2018-07-19 2019-07-19 Interconnected active ingredient containing pouches
EP19742738.8A EP3823473A1 (fr) 2018-07-19 2019-07-19 Poches contenant un principe actif reliées entre elles
RU2021104128A RU2769307C1 (ru) 2018-07-19 2019-07-19 Соединенные между собой пакетики с активным ингредиентом
MX2021000772A MX2021000772A (es) 2018-07-19 2019-07-19 Bolsas interconectadas que contienen ingredientes activos.
CA3106859A CA3106859C (fr) 2018-07-19 2019-07-19 Poches contenant un principe actif reliees entre elles
JP2022190090A JP2023022200A (ja) 2018-07-19 2022-11-29 相互接続された活性成分含有パウチ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201870490 2018-07-19
DKPA201870490 2018-07-19

Publications (1)

Publication Number Publication Date
WO2020016432A1 true WO2020016432A1 (fr) 2020-01-23

Family

ID=67402938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/069559 WO2020016432A1 (fr) 2018-07-19 2019-07-19 Poches contenant un principe actif reliées entre elles

Country Status (7)

Country Link
US (1) US20210235752A1 (fr)
EP (1) EP3823473A1 (fr)
JP (2) JP7197071B2 (fr)
CA (1) CA3106859C (fr)
MX (1) MX2021000772A (fr)
RU (1) RU2769307C1 (fr)
WO (1) WO2020016432A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022229926A1 (fr) * 2021-04-30 2022-11-03 Nicoventures Trading Limited Produit en sachet destiné à être administré par voie orale à plusieurs compartiments

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004095959A1 (fr) * 2003-04-29 2004-11-11 Swedish Match North Europe Ab Produit tabac sans fumee oral et son procede de production
WO2008016520A2 (fr) * 2006-08-01 2008-02-07 R.J. Reynolds Tobacco Company Tabac sans fumée
US20120031414A1 (en) * 2010-08-05 2012-02-09 U.S. Smokeless Tobacco Company Llc Composite smokeless tobacco products, systems, and methods
WO2016097007A1 (fr) * 2014-12-19 2016-06-23 Jt International Sa Récipient à tabac sans fumée
EP3087852A1 (fr) * 2015-04-17 2016-11-02 Swedish Match North Europe AB Produit en sachet oral présentant une forme rectangulaire

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100402624B1 (en) * 2003-04-28 2003-10-17 Kwang Hwan Jeong Processing method for garlic
BRPI0516732A (pt) * 2004-09-30 2008-09-23 Hershey Co embalagens vedadas de tiras de filme comestìves e métodos para fazer e usar as mesmas
WO2011108385A1 (fr) * 2010-03-04 2011-09-09 日本たばこ産業株式会社 Dispositif de porte-produit à usage oral
US8268370B2 (en) * 2010-03-26 2012-09-18 Philip Morris Usa Inc. Solid oral sensorial products including stain inhibitor
US9414624B2 (en) * 2013-03-14 2016-08-16 Altria Client Services Llc Fiber-wrapped smokeless tobacco product
WO2016099960A1 (fr) * 2014-12-16 2016-06-23 Goode Read Fisher Jr Produit de sachet oral sans couture
US11612183B2 (en) * 2015-12-10 2023-03-28 R.J. Reynolds Tobacco Company Protein-enriched tobacco composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004095959A1 (fr) * 2003-04-29 2004-11-11 Swedish Match North Europe Ab Produit tabac sans fumee oral et son procede de production
WO2008016520A2 (fr) * 2006-08-01 2008-02-07 R.J. Reynolds Tobacco Company Tabac sans fumée
US20120031414A1 (en) * 2010-08-05 2012-02-09 U.S. Smokeless Tobacco Company Llc Composite smokeless tobacco products, systems, and methods
WO2016097007A1 (fr) * 2014-12-19 2016-06-23 Jt International Sa Récipient à tabac sans fumée
EP3087852A1 (fr) * 2015-04-17 2016-11-02 Swedish Match North Europe AB Produit en sachet oral présentant une forme rectangulaire

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022229926A1 (fr) * 2021-04-30 2022-11-03 Nicoventures Trading Limited Produit en sachet destiné à être administré par voie orale à plusieurs compartiments

Also Published As

Publication number Publication date
MX2021000772A (es) 2021-03-29
US20210235752A1 (en) 2021-08-05
JP7197071B2 (ja) 2022-12-27
JP2023022200A (ja) 2023-02-14
JP2021531818A (ja) 2021-11-25
EP3823473A1 (fr) 2021-05-26
CA3106859C (fr) 2023-07-25
CA3106859A1 (fr) 2020-01-23
RU2769307C1 (ru) 2022-03-30

Similar Documents

Publication Publication Date Title
US11318125B2 (en) Multi-phase delivery compositions and products incorporating such compositions
US10219537B2 (en) Smokeless tobacco composition
EP2173200B1 (fr) Composition de tabac sans fumée, et procédés pour traiter le tabac destiné à y être utilisé
US7946295B2 (en) Smokeless tobacco composition
US7810507B2 (en) Smokeless tobacco composition
EP1926401B1 (fr) Composition de tabac qui ne se fume pas
DK2173200T3 (en) Smokeless tobacco compositions and methods of treating tobacco for use therein
US20080166395A1 (en) Article for delivering substrates to the oral cavity
KR100370340B1 (ko) 담배 대용 조성물
WO2009010884A2 (fr) Produit en sachet pour l'administration orale d'arôme exempt de tabac
WO2012177510A2 (fr) Composition d'alcaloïdes pour cigarette électronique
US20050034738A1 (en) Chewing tobacco substitute containing nicotine
WO2021111140A1 (fr) Composition de tabac
JP2023022200A (ja) 相互接続された活性成分含有パウチ
US20060112965A1 (en) Chewing tobacco substitute containing cotinine
CN107950740A (zh) 一种富含硒的烟草口香糖
JP2023507505A (ja) 非燃焼系エアロゾル供給システムで使用される粒子の集団
EP4371421A1 (fr) Récipient de produit en sachet de nicotine, et procédé de consommation de produits en sachet de type nicotine
RU2779390C1 (ru) Пакетированный продукт, подходящий для применения в ротовой полости

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19742738

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 3106859

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2019742738

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2021512494

Country of ref document: JP

Kind code of ref document: A